Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Southern Company
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
Allos Therapeutics has achieved its goal of securing a strategic ex-US partner for its peripheral T-cell lymphoma (PTCL) drug Folotyn (pralatrexate), signing a deal granting Mundipharma International certain rights to co-develop and commercialise the product.
- Other Names / Subsidiaries
- Nacogdoches Power, LLC